Abstract
Objectives:
To identify the incidence, characteristics and factors associated with against medical advice (AMA) discharge among hospitalized patients with opioid use disorder (OUD) and injection related infections (e.g., endocarditis, osteomyelitis, epidural abscesses).
Methods:
This retrospective cohort study evaluated adults with OUD admitted to an academic medical center from 1/1/2016-7/1/2019 for an invasive injection related infection. Multivariable logistic regression was used to determine independent factors associated with AMA discharge.
Results:
Among 262 adults admitted with serious injection related infections and comorbid OUD, 138 received inpatient medications for opioid use disorder (MOUD). Univariate analysis showed a decreased odds ratio (OR) of AMA discharge when patients received MOUD inpatient (OR 0.55; 95% CI 0.34-0.91.). Adjusting for covariates associated with social determinants of health and other substance use, inpatient receipt of MOUD was associated with a decreased risk of AMA discharge (adjusted OR 0.49; 95% CI 0.028 – 0.84).
Conclusions:
Among patients with OUD and serious injection related infections, inpatient initiation of MOUD is associated with decreased risk of AMA discharge.
Keywords: persons who inject drugs, opioid use disorder, endocarditis, osteomyelitis
Introduction:
The United States is facing an opioid-related overdose crisis so severe it may be contributing to the first decline in US life expectancy.1 Persons who inject opioids are at increased risk of invasive infections, including endocarditis, epidural abscess, septic arthritis, and osteomyelitis. The care of persons who inject drugs (PWID) requires special considerations about treatment and risk mitigation. For example, due to safety concerns, most infectious disease specialists recommend that intravenous (IV) antibiotics for injection related infections be completed in an inpatient or other supervised setting.2 The result is that hospitalizations for PWID are longer, requiring 4-6 weeks of inpatient care in order to complete IV antibiotic therapy. Persons who inject opioids are at increased risk for leaving the hospital against medical advice (AMA), frequently before completing adequate therapy for their illness.3 AMA discharge, for any condition, has been associated with increased risk for readmission and all-cause mortality.4,5
Despite frequent hospitalizations and high healthcare costs, most hospitalized patients with opioid use disorder (OUD) are not engaged in OUD care prior to discharge.6,7 Many patients with OUD find the experience of admission to be traumatic, particularly with regard to undertreatment of pain and increased scrutiny from staff.8 With increasing attention focused on improving care for this vulnerable population, integration of medications for opioid use disorder (MOUD) into inpatient care has been recommended.9 However, few studies have addressed impact of MOUD initiation on retention in inpatient care. Suzuki et al. recently reported that MOUD use was not associated with a decrease in AMA discharges in persons with injection drug use associated endocarditis.10 However, the sample size for this study was small and how MOUDs were incorporated into a patient-centered care model was unclear. The objective of this study was to evaluate the impact of initiation of MOUD on AMA discharges among PWID with serious injection related infections.
Methods:
We performed a retrospective chart review of PWID with OUD admitted with invasive bacterial infections between January 2016 and July 2019 to Barnes-Jewish Hospital (BJH), a 1400-bed, academic, tertiary center in St. Louis, Missouri. All patients documented on admission with a concern for injection related infection in the electronic medical record were included in our database. Those who received an infectious diseases (ID) consultation for endocarditis, epidural abscess, septic arthritis, Staphylococcus aureus bacteremia and osteomyelitis were identified as previously described.11 Admissions were individually chart reviewed by an author (LRM) and only those with confirmation of opioid related injection drug associated infection were included in this cohort. Two other physicians (NSN and MJD) reviewed 10% of charts at random to assess for data concordance with inclusion criteria. Patient demographics, clinical covariates, and outcomes data were collected.
The primary outcome studied was AMA discharge. Demographic and clinical characteristics were compared for all patients by therapy group using Fisher’s exact tests and Mann-Whitney U test for categorical variables and continuous variables, respectively. In the secondary analysis, we used multivariable logistic regression models to explore associations with AMA discharges. We focused on social determinants of health and comorbid non-opioid substance use in the multivariable model. Specific factors were selected based on univariate results, underlying causal structure and our clinical observations as physicians. All tests for significance were performed using SPSS version 25 and were 2-tailed, with p < 0.05 considered significant. This study was approved by the Washington University Institutional Review Board.
Results:
Two-hundred and seventy-six unique admissions for PWID with invasive infections were identified during the study period. Fourteen patients died during the initial inpatient encounter and were excluded as the impact of MOUD on AMA discharge could not be assessed. Of the remaining 262 admissions included in the study, 107 patients (40.8%) left AMA during the study period. Baseline characteristics are presented in Table 1. Most patients who received MOUD had an associated addiction medicine consult (84.8%). Of those who received MOUD, 66 (47.8%) received buprenorphine or buprenorphine-naloxone, 56 (40.6%) received methadone, and 16 (11.6%) received a methadone in-hospital taper. Adjusting for social determinants of health and comorbid non-opioid substance use, multivariable analysis identified a significantly lower AMA discharge rate associated with receipt of MOUD (aOR = 0.49; 95% CI 0.28 – 0.84). Uninsured status (aOR = 4.10; 95% CI = 2.22 – 7.58) and female gender (aOR 2.37; 95% CI = 1.34 – 4.20) were also associated with AMA discharge. Housing status was not associated with AMA discharge. Concurrent methamphetamine use, in addition to injection opioid use, was correlated with increased risk of AMA discharge (aOR = 2.06; 95% CI 1.10 – 3.87).
Table 1.
Baseline demographics and univariate analysis of predictors of discharge against medical advice stratified by receipt of medications for opioid use disorder.
| Baseline characteristics | |||
|---|---|---|---|
| Inpatient MOUD N=138 |
No MOUD N=124 |
P value | |
| Demographics | |||
| Age (mean, SD) | 38±9 | 41±12 | 0.040 |
| Female | 83 (60.1%) | 51 (41.1%) | 0.002 |
| African American | 58 (42.0%) | 49 (39.5%) | 0.261 |
| Unstable Housing | 23 (16.7%) | 15 (12.1%) | 0.294 |
| Uninsured | 36 (26.1%) | 43 (34.7%) | 0.140 |
| Received Addiction Med Consult | 117 (84.8%) | 13 (10.5%) | <.001 |
| Substance Use Patterns | |||
| Prior IDU-related infections | 109 (79.0%) | 67 (54.0%) | <.001 |
| Opioid Use (fentanyl or heroin) without other substances | 72 (52.2%) | 71 (57.2%) | 0.409 |
| Opioids + Methamphetamines | 30 (21.7%) | 33 (26.6%) | 0.357 |
| Opioids + Cocaine | 42 (30.4%) | 25 (20.2%) | 0.570 |
| Opioids + Benzodiazepines | 0 (0%) | 3 (2.4%) | 0.066 |
| Comorbidities | |||
| Hypertension | 14 (10.1%) | 17 (13.7%) | 0.372 |
| Diabetes Mellitus | 6 (4.3%) | 12 (9.7%) | 0.089 |
| Psychiatric comorbidity | 12 (8.7%) | 18 (14.5%) | 0.140 |
| Hepatitis C infection | 111 (80.4%) | 63 (50.8%) | <.001 |
| HIV infection | 7 (5.1%) | 5 (4.0%) | 0.688 |
| Type of Serious Injection Related Infection | |||
| Infective endocarditis | 88 (63.8%) | 65 (52.4%) | 0.063 |
| Osteomyelitis | 49 (35.5%) | 37 (29.8%) | 0.329 |
| Septic Arthritis | 20 (15.5%) | 25 (20.2%) | 0.225 |
| Epidural Abscess | 15 (11.1%) | 15 (12.1%) | 0.755 |
| Isolated Bacteremia | 6 (4.3%) | 8 (6.5%) | 0.450 |
| Staphylococcus aureus infection | 94 (68.1%) | 79 (63.7%) | 0.452 |
| Outcomes | |||
| AMA Discharge | 47 (34.1%) | 60 (48.4%) | 0.018 |
| Number of Days left in hospitalization if leaving AMA (Mean, SD) | 11±14 | 18±17 | 0.001 |
| Average Length of Stay (Mean, SD) | 30±12 | 25±13 | 0.029 |
Overall, 64% of AMA discharges were related to opioid withdrawal, with 22% related to social issues (e.g., child-care, potential loss of employment or housing and court appointments) and an additional 10% related to conflicts with staff. The remaining discharges did not have any documentation regarding the reason for AMA discharge. Among patients not prescribed MOUD, 73% of discharges were related to opioid withdrawal or cravings compared to 21% among those prescribed MOUD (P<0.001).
Discussion:
In this retrospective study of 262 patients admitted for invasive injection related infection, receipt of MOUD during inpatient hospitalization was associated with decreased risk of AMA discharge. The most common reason for AMA discharge among PWID with injection related infections was opioid withdrawal or cravings. However, social issues, such as the need for child-care and potential loss of employment or housing, were also significant drivers of AMA discharges.
While our results differed from recent data published by Suzuki et al.,10 which did not find a significant difference between those receiving MOUD treatment and rate of AMA discharge, we agree that initiation of MOUD represents only one aspect of the comprehensive care needed during an inpatient encounter.10 An observation in working with this population has been their diverse and often unique social needs. For example, we observed that female gender was associated with increased risk of AMA discharge, often with associated concern of childcare. This represents the frequent disparity of resources and support networks available to those struggling with addiction. Additional studies specifically evaluating the role for and impact of health navigators, case managers, therapist and addiction medicine professionals are needed to identify optimal care pathways for this population.
There are notable trends when comparing the characteristics of those who received inpatient MOUD. Patients with multiple prior admissions for injection related infections and those with Hepatitis C virus infection were much more likely to be treated with inpatient MOUD. This suggests missed opportunities to engage patients earlier in their illness. MOUD initiation has been associated with reduction in risk for acquiring Hepatitis C infection.12 The delay in prescription of MOUD may be related to biases about addiction severity and lack of education on benefits of MOUDs. Specifically, some providers may not perceive first time admissions to warrant referral for addiction services. Alternatively, patients may be less likely to engage in addiction treatment prior to recurrent and obvious complications.
Limitations of this study include its single center retrospective design; our data may not be generalizable to other institutions. Substance use patterns vary widely across different geographic areas.13 It was notable that in this cohort, concurrent use of methamphetamines was associated with AMA discharge. Data on patients offered MOUD but who declined treatment may not be captured in the chart review.
Conclusions:
Our study suggests that MOUDs decrease AMA discharge. We recommended larger, multicenter and possibly randomized-controlled trials to further investigate this question. Based on available evidence, we believe physicians should consider initiation of MOUD as part of a comprehensive approach to caring for persons with injection opioid related infections.
Table 2:
Univariate and multivariable analyses for risk of AMA discharge
| Univariate analysis | Multivariable Logistic Regression Model | |||
|---|---|---|---|---|
| OR (95% CI) for AMA discharge |
P value | aOR (95% CI) for AMA discharge |
P value | |
| Received MOUD | 0.55 (0.34 −0.91) | 0.013 | 0.49 (0.028 – 0.84) | 0.009 |
| Female | 1.69 (1.03 – 2.79) | 0.038 | 2.37 (1.34– 4.20) | 0.003 |
| Unstable Housing | 0.85 (0.54 −1.32) | 0.489 | 1.39 (0.62 – 3.12) | 0.422 |
| Uninsured | 3.93 (2.17 – 7.13) | 0.001 | 4.10 (2.22 - 7.58) | <.001 |
| Opioid Use (fentanyl or heroin) without other substances | 0.54 (0.34 – 0.87) | 0.013 | 0.837 (0.173 – 4.062) | 0.825 |
| Opioids + Methamphetamines | 1.86 (1.05 – 3.29) | 0.0337 | 1.83 (0.99 – 3.41) | 0.056 |
| Opioids + Cocaine | 1.35 (0.77 – 2.36) | 0.2955 | 1.38 (0.73 – 2.59) | 0.324 |
OR – Odds Ratio; aOR – Adjusted Odds Ratio; adjusted for receipt of MOUD, health insurance status, homelessness, gender, and substance use patterns.
Acknowledgments
Funding Sources: This work was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under grant numbers [KL2TR002346, and T32AI007172]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Footnotes
Conflicts of Interest: None
Citations:
- 1.Woolf SH, Schoomaker H. Life Expectancy and Mortality Rates in the United States, 1959-2017. JAMA - Journal of the American Medical Association. 2019;322(20):1996–2016. doi: 10.1001/jama.2019.16932 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Rapoport AB, Fischer LS, Santibanez S, Beekmann SE, Polgreen PM, Rowley CF. Infectious diseases physicians’ perspectives regarding injection drug use and related infections, United States, 2017. Open Forum Infectious Diseases. 2018;5(7):1–10. doi: 10.1093/ofid/ofy132 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: A systematic review. American Journal of Public Health. 2015;105(12):e53–e59. doi: 10.2105/AJPH.2015.302885 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Glasgow JM, Vaughn-Sarrazin M, Kaboli PJ. Leaving against medical advice (AMA): Risk of 30-day mortality and hospital readmission. Journal of General Internal Medicine. 2010;25(9):926–929. doi: 10.1007/s11606-010-1371-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Choi M, Kim H, Qian H, Palepu A. Readmission rates of patients discharged against medical advice: A matched cohort study. PLoS ONE. 2011;6(9):2–7. doi: 10.1371/journal.pone.0024459 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rosenthal ES, Karchmer AW, Theisen-Toupal J, Castillo RA, Rowley CF. Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis. American Journal of Medicine. 2016;129(5):481–485. doi: 10.1016/j.amjmed.2015.09.024 [DOI] [PubMed] [Google Scholar]
- 7.Serota DP, Niehaus ED, Schechter MC, et al. Disparity in Quality of Infectious Disease vs Addiction Care Among Patients With Injection Drug Use–Associated Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases. 2019;6(7):1–4. doi: 10.1093/ofid/ofz289 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.McNeil R, Small W, Wood E, Kerr T. Hospitals as a “risk environment”: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Social science & medicine (1982). 2014;105(2):59–66. doi: 10.1016/j.socscimed.2014.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Thakarar K, Weinstein ZM, Walley AY. Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. Postgraduate Medical Journal. 2016;92(1088):356–363. doi: 10.1136/postgradmedj-2015-133720 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Suzuki J, Robinson D, Mosquera M, et al. Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis. The American Journal on Addictions. 2020:1–5. doi: 10.1111/ajad.13000 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction Medicine Consultations Reduce Readmission Rates for Patients with Serious Infections from Opioid Use Disorder. Clinical Infectious Diseases. 2019;68(11):1935–1937. doi: 10.1093/cid/ciy924 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in young adult persons who inject drugs HHS Public Access. JAMA Intern Med. 2014;174(12):1974–1981. doi: 10.1001/jamainternmed.2014.5416 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Office of Applied Studies. Substance Abuse and Mental Health Services Administration (2005) Results from the 2004 National Survey on Drug Use and Health. DHHS Publication: Rockville, MD, USA. 2005. [Google Scholar]